Download - Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.

Transcript
Page 1: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 2: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 3: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 4: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 5: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 6: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 7: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 8: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 9: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 10: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 11: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 12: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.

Top Related

Camptocormia and Parkinson’s disease: MR imaging

Camptocormia and Parkinson’s disease: MR imaging

SPECT neuroimaging and neuropsychological functions in different stages of Parkinson’s disease

SPECT neuroimaging and neuropsychological functions in different stages of Parkinson’s disease

Euodenine A: A Small-Molecule Agonist of Human TLR4

Euodenine A: A Small-Molecule Agonist of Human TLR4

Sleep problems reported by patients entering opioid agonist treatment

Sleep problems reported by patients entering opioid agonist treatment

A Galanin Receptor Subtype 1 Specific Agonist

A Galanin Receptor Subtype 1 Specific Agonist

Common pathophysiological mechanisms of primary headache and Parkinson’s disease – a neurophysiological evidence.

Common pathophysiological mechanisms of primary headache and Parkinson’s disease – a neurophysiological evidence.

Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients

Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients

Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson’s disease

Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson’s disease

Bahasa
Halaman
Hukum

Copyright © 2022 FDOKUMEN